U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C12H22O11
Molecular Weight 342.2965
Optical Activity UNSPECIFIED
Defined Stereocenters 8 / 8
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of LACTULOSE

SMILES

[H][C@@](O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O)([C@H](O)CO)[C@H](O)C(=O)CO

InChI

InChIKey=PFCRQPBOOFTZGQ-VZXVHDRGSA-N
InChI=1S/C12H22O11/c13-1-4(16)7(18)11(5(17)2-14)23-12-10(21)9(20)8(19)6(3-15)22-12/h5-15,17-21H,1-3H2/t5-,6-,7-,8+,9+,10-,11-,12+/m1/s1

HIDE SMILES / InChI
Lactulose is a non-absorbable sugar used in the treatment of constipation and hepatic encephalopathy. It is a disaccharide (double-sugar) formed from one molecule each of the simple sugars (monosaccharides) fructose and galactose. Lactulose is not normally present in raw milk but is a product of heat-processed: the greater the heat, the greater amount of this substance. Lactulose is not absorbed in the small intestine nor broken down by human enzymes, thus stays in the digestive bolus through most of its course, causing retention of water through osmosis leading to softer, easier to pass stool. It has a secondary laxative effect in the colon, where it is fermented by the gut flora, producing metabolites which have osmotic powers and peristalsis-stimulating effects (such as acetate), but also methane associated with flatulence. Lactulose is metabolized in the colon by bacterial flora to short chain fatty acids including lactic acid and acetic acid. These partially dissociate, acidifying the colonic contents (increasing the H+ concentration in the gut).[14] This favors the formation of the nonabsorbable NH+4 from NH3, trapping NH3 in the colon and effectively reducing plasma NH3 concentrations. Lactulose is used in the treatment of chronic constipation in patients of all ages as a long-term treatment. Lactulose is used for chronic idiopathic constipation, i.e. chronic constipation occurring without any identifiable cause. Lactulose may be used to counter the constipating effects of opioids, and in the symptomatic treatment of hemorrhoids as a stool softener.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
CEPHULAC

Approved Use

For the prevention and treatment of portal-systemic encephalopathy, including the stages of hepatic pre-coma and coma. Controlled studies have shown that lactulose solution therapy reduces the blood ammonia levels by 25-50%; this is generally paralleled by an improvement in the patients' mental state and by an improvement in EEG patterns. The clinical response has been observed in about 75% of patients, which is at least as satisfactory as that resulting from neomycin therapy. An increase in patients' protein tolerance is also frequently observed with lactulose therapy. In the treatment of chronic portal-systemic encephalopathy, Lactulose has been given for over 2 years in controlled studies.

Launch Date

1976
Primary
CEPHULAC

Approved Use

For the prevention and treatment of portal-systemic encephalopathy, including the stages of hepatic pre-coma and coma. Controlled studies have shown that lactulose solution therapy reduces the blood ammonia levels by 25-50%; this is generally paralleled by an improvement in the patients' mental state and by an improvement in EEG patterns. The clinical response has been observed in about 75% of patients, which is at least as satisfactory as that resulting from neomycin therapy. An increase in patients' protein tolerance is also frequently observed with lactulose therapy. In the treatment of chronic portal-systemic encephalopathy, Lactulose has been given for over 2 years in controlled studies.

Launch Date

1976
PubMed

PubMed

TitleDatePubMed
The effect of antenatal vitamin A and beta-carotene supplementation on gut integrity of infants of HIV-infected South African women.
2001 Apr
Clostridial constipation's broad pathology.
2001 Apr
Lactose malabsorption and intolerance in the elderly.
2001 Dec
Use of an orally administered combined sugar solution to evaluate intestinal absorption and permeability in cats.
2001 Jan
[Intestinal permeability in Crohn's disease and effects of elemental dietary therapy].
2001 Jun
Lactulose may help prevent urinary tract infections.
2001 Oct 20
Typhoid, hepatitis E, or typhoid and hepatitis E: the cause of fulminant hepatic failure--a diagnostic dilemma.
2002 Feb
Small intestinal bacterial overgrowth, intestinal permeability, and non-alcoholic steatohepatitis.
2002 Jan
Evaluation of hydrogen excretion after lactulose administration as a screening test for causes of irritable bowel syndrome.
2002 Jul
The relationships between intestinal damage and circulating endotoxins in experimental Trypanosoma brucei brucei infections.
2002 Jun
[Hepatic encephalopathy after TIPS--retrospective study].
2002 May
Patents

Sample Use Guides

The usual adult, oral dosage is 2 to 3 tablespoonfuls (30 mL to 45 mL, containing 20 grams to 30 grams of Lactulose) three or four times daily. The dosage may be adjusted every day or two to produce 2 or 3 soft stools daily.
Route of Administration: Oral
In Vitro Use Guide
Unknown
Name Type Language
LACTULOSE
EP   INCI   INN   MART.   MI   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD  
USAN   INN   INCI  
Official Name English
LACTULOSE [EP MONOGRAPH]
Common Name English
LACTULOSE [ORANGE BOOK]
Common Name English
LACTULOSE [EP IMPURITY]
Common Name English
LACTULOSE [USP IMPURITY]
Common Name English
CONSTILAC
Brand Name English
LACTULOSE [JAN]
Common Name English
ENULOSE
Brand Name English
lactulose [INN]
Common Name English
4-O-.BETA.-D-GALACTOPYRANOSYL-D-FRUCTOFURANOSE
Common Name English
ACILAC
Brand Name English
LACTULOSE [INCI]
Common Name English
LAXILOSE
Brand Name English
CONSTULOSE
Brand Name English
LACTULOSE [VANDF]
Common Name English
CEPHULAC
Brand Name English
EVALOSE
Brand Name English
LACTULOSE [USAN]
Common Name English
4-GALACTOSYL FRUCTOSE
Common Name English
LACTULOSE [MI]
Common Name English
GENERLAC
Brand Name English
CHRONULAC
Brand Name English
NSC-757082
Code English
LACTULOSE JP17 [JAN]
Common Name English
LACTULOSE [MART.]
Common Name English
PORTALAC
Brand Name English
Lactulose [WHO-DD]
Common Name English
DUPHALAC
Brand Name English
CHOLAC
Brand Name English
HEPTALAC
Brand Name English
D-FRUCTOSE, 4-O-.BETA.-D-GALACTOPYRANOSYL-
Common Name English
Classification Tree Code System Code
WHO-VATC QA06AD11
Created by admin on Sat Dec 16 18:25:25 GMT 2023 , Edited by admin on Sat Dec 16 18:25:25 GMT 2023
LOINC 74900-2
Created by admin on Sat Dec 16 18:25:25 GMT 2023 , Edited by admin on Sat Dec 16 18:25:25 GMT 2023
WHO-ATC A06AD61
Created by admin on Sat Dec 16 18:25:25 GMT 2023 , Edited by admin on Sat Dec 16 18:25:25 GMT 2023
NCI_THESAURUS C68472
Created by admin on Sat Dec 16 18:25:25 GMT 2023 , Edited by admin on Sat Dec 16 18:25:25 GMT 2023
WHO-ATC A06AD11
Created by admin on Sat Dec 16 18:25:25 GMT 2023 , Edited by admin on Sat Dec 16 18:25:25 GMT 2023
NDF-RT N0000175811
Created by admin on Sat Dec 16 18:25:25 GMT 2023 , Edited by admin on Sat Dec 16 18:25:25 GMT 2023
NCI_THESAURUS C29697
Created by admin on Sat Dec 16 18:25:25 GMT 2023 , Edited by admin on Sat Dec 16 18:25:25 GMT 2023
WHO-ESSENTIAL MEDICINES LIST 8.4
Created by admin on Sat Dec 16 18:25:25 GMT 2023 , Edited by admin on Sat Dec 16 18:25:25 GMT 2023
WHO-VATC QA06AD61
Created by admin on Sat Dec 16 18:25:25 GMT 2023 , Edited by admin on Sat Dec 16 18:25:25 GMT 2023
LOINC 74899-6
Created by admin on Sat Dec 16 18:25:25 GMT 2023 , Edited by admin on Sat Dec 16 18:25:25 GMT 2023
Code System Code Type Description
RXCUI
6218
Created by admin on Sat Dec 16 18:25:25 GMT 2023 , Edited by admin on Sat Dec 16 18:25:25 GMT 2023
PRIMARY RxNorm
NCI_THESAURUS
C29148
Created by admin on Sat Dec 16 18:25:25 GMT 2023 , Edited by admin on Sat Dec 16 18:25:25 GMT 2023
PRIMARY
INN
2137
Created by admin on Sat Dec 16 18:25:25 GMT 2023 , Edited by admin on Sat Dec 16 18:25:25 GMT 2023
PRIMARY
EPA CompTox
DTXSID5045833
Created by admin on Sat Dec 16 18:25:25 GMT 2023 , Edited by admin on Sat Dec 16 18:25:25 GMT 2023
PRIMARY
DRUG CENTRAL
1536
Created by admin on Sat Dec 16 18:25:25 GMT 2023 , Edited by admin on Sat Dec 16 18:25:25 GMT 2023
PRIMARY
EVMPD
SUB08386MIG
Created by admin on Sat Dec 16 18:25:25 GMT 2023 , Edited by admin on Sat Dec 16 18:25:25 GMT 2023
PRIMARY
PUBCHEM
3037557
Created by admin on Sat Dec 16 18:25:25 GMT 2023 , Edited by admin on Sat Dec 16 18:25:25 GMT 2023
PRIMARY PUBCHEM
MESH
D007792
Created by admin on Sat Dec 16 18:25:25 GMT 2023 , Edited by admin on Sat Dec 16 18:25:25 GMT 2023
PRIMARY
MERCK INDEX
m6665
Created by admin on Sat Dec 16 18:25:25 GMT 2023 , Edited by admin on Sat Dec 16 18:25:25 GMT 2023
PRIMARY Merck Index
DRUG BANK
DB00581
Created by admin on Sat Dec 16 18:25:25 GMT 2023 , Edited by admin on Sat Dec 16 18:25:25 GMT 2023
PRIMARY
NSC
757082
Created by admin on Sat Dec 16 18:25:25 GMT 2023 , Edited by admin on Sat Dec 16 18:25:25 GMT 2023
PRIMARY
CHEBI
6359
Created by admin on Sat Dec 16 18:25:25 GMT 2023 , Edited by admin on Sat Dec 16 18:25:25 GMT 2023
PRIMARY
SMS_ID
100000091634
Created by admin on Sat Dec 16 18:25:25 GMT 2023 , Edited by admin on Sat Dec 16 18:25:25 GMT 2023
PRIMARY
DAILYMED
9U7D5QH5AE
Created by admin on Sat Dec 16 18:25:25 GMT 2023 , Edited by admin on Sat Dec 16 18:25:25 GMT 2023
PRIMARY
ECHA (EC/EINECS)
225-027-7
Created by admin on Sat Dec 16 18:25:25 GMT 2023 , Edited by admin on Sat Dec 16 18:25:25 GMT 2023
PRIMARY
FDA UNII
9U7D5QH5AE
Created by admin on Sat Dec 16 18:25:25 GMT 2023 , Edited by admin on Sat Dec 16 18:25:25 GMT 2023
PRIMARY
WIKIPEDIA
LACTULOSE
Created by admin on Sat Dec 16 18:25:25 GMT 2023 , Edited by admin on Sat Dec 16 18:25:25 GMT 2023
PRIMARY
RS_ITEM_NUM
1356803
Created by admin on Sat Dec 16 18:25:25 GMT 2023 , Edited by admin on Sat Dec 16 18:25:25 GMT 2023
PRIMARY
EVMPD
SUB12100MIG
Created by admin on Sat Dec 16 18:25:25 GMT 2023 , Edited by admin on Sat Dec 16 18:25:25 GMT 2023
ALTERNATIVE
ChEMBL
CHEMBL296306
Created by admin on Sat Dec 16 18:25:25 GMT 2023 , Edited by admin on Sat Dec 16 18:25:25 GMT 2023
PRIMARY
CAS
4618-18-2
Created by admin on Sat Dec 16 18:25:25 GMT 2023 , Edited by admin on Sat Dec 16 18:25:25 GMT 2023
PRIMARY